Atea Pharmaceuticals (AVIR) Shares Outstanding (2019 - 2026)

Atea Pharmaceuticals' Shares Outstanding (Entity) history runs 8 years deep, the most recent figure standing at $80.0 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) fell 6.49% year-over-year to $80.0 million; the TTM figure through Mar 2026 stood at $80.0 million (down 6.49% YoY), while the FY2025 annual figure was $78.1 million, down 7.5% from the prior year.
• Shares Outstanding (Entity) for Q1 2026 stood at $80.0 million, up from $78.1 million in the prior quarter.
• The five-year high for Shares Outstanding (Entity) was $85.6 million in Q1 2025, with the low at $78.1 million in Q3 2025.
• The 5-year median for Shares Outstanding (Entity) is $83.4 million (2023), against an average of $82.8 million.
• Peak annual rise in Shares Outstanding (Entity) reached 1.61% in 2025, while the deepest fall reached 7.5% in 2025.
• Atea Pharmaceuticals' Shares Outstanding (Entity) stood at $83.3 million in 2022, then gained by 0.18% to $83.4 million in 2023, then increased by 1.23% to $84.5 million in 2024, then retreated by 7.5% to $78.1 million in 2025, then gained by 2.43% to $80.0 million in 2026.
• Business Quant data shows AVIR's Shares Outstanding (Entity) at $80.0 million in Q1 2026, $78.1 million in Q4 2025, and $78.1 million in Q3 2025.